Corbus Pharmaceuticals Company Insiders
CRBP Stock | USD 8.50 0.04 0.47% |
Corbus Pharmaceuticals employs about 28 people. The company is managed by 10 executives with a total tenure of roughly 7 years, averaging almost 0.0 years of service per executive, having 2.8 employees per reported executive. Discussion of Corbus Pharmaceuticals' management performance can provide insight into the enterprise performance.
Yuval Cohen CEO CEO and Director |
Insider Sentiment 50
Impartial
Selling | Buying |
Latest Trades
2025-05-30 | John Kenneth Jenkins | Disposed 2783 @ 7.35 | View | ||
2024-09-20 | Cormorant Asset Management, Lp | Acquired 350000 @ 20.01 | View |
Monitoring Corbus Pharmaceuticals' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Corbus Pharmaceuticals Holding. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. Corbus Pharmaceuticals' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Corbus Pharmaceuticals' future performance. Based on our forecasts, it is anticipated that Corbus will maintain a workforce of slightly above 30 employees by August 2025.Corbus Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of (0.2718) % which means that it has lost $0.2718 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4489) %, meaning that it created substantial loss on money invested by shareholders. Corbus Pharmaceuticals' management efficiency ratios could be used to measure how well Corbus Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of 07/20/2025, Return On Tangible Assets is likely to drop to -0.27. In addition to that, Return On Capital Employed is likely to drop to -0.36. At this time, Corbus Pharmaceuticals' Total Current Liabilities is relatively stable compared to the past year. As of 07/20/2025, Liabilities And Stockholders Equity is likely to grow to about 163.7 M, while Non Current Liabilities Total is likely to drop slightly above 1.6 M.As of 07/20/2025, Common Stock Shares Outstanding is likely to grow to about 11.5 M, while Net Loss is likely to drop (40 M).
Corbus Pharmaceuticals Workforce Comparison
Corbus Pharmaceuticals Holding is rated fifth in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 344. Corbus Pharmaceuticals holds roughly 28.0 in number of employees claiming about 8% of equities under Health Care industry.
Corbus Pharmaceuticals Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Corbus Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Corbus Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Corbus Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2025-03-01 | 2.0 | 6 | 3 | 535,300 | 16,319 |
2024-06-01 | 1.35 | 27 | 20 | 116,638 | 117,910 |
2024-03-01 | 16.5 | 33 | 2 | 1,918,686 | 7,808 |
2020-12-01 | 0.6667 | 4 | 6 | 182,273 | 356,066 |
2019-09-01 | 2.0 | 6 | 3 | 120,814 | 120,000 |
2018-12-01 | 1.0 | 1 | 1 | 10,000 | 10,000 |
2018-06-01 | 11.0 | 11 | 1 | 437,311 | 220,000 |
2017-03-01 | 7.0 | 7 | 1 | 748,733 | 20,000 |
2016-09-01 | 8.0 | 8 | 1 | 307,460 | 20,000 |
2015-12-01 | 16.0 | 16 | 1 | 21,085 | 375.00 |
2015-09-01 | 9.0 | 27 | 3 | 193,050 | 240,000 |
2015-06-01 | 7.0 | 7 | 1 | 95,650 | 50,000 |
2014-12-01 | 1.4091 | 31 | 22 | 104,662 | 1,993,791 |
Corbus Pharmaceuticals Notable Stakeholders
A Corbus Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Corbus Pharmaceuticals often face trade-offs trying to please all of them. Corbus Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Corbus Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Yuval Cohen | CEO and Director | Profile | |
Ted Jenkins | Senior Director, Investor Relations and Communications | Profile | |
MD MA | Chief Officer | Profile | |
Christina Bertsch | Head Resources | Profile | |
CPA MBA | Chief Officer | Profile | |
Rachael Brake | Chief Officer | Profile | |
Lindsey Smith | Head Advocacy | Profile | |
Ian Hodgson | Chief Officer | Profile | |
Scott Constantine | Director Operations | Profile | |
Craig MBA | Chief Officer | Profile |
About Corbus Pharmaceuticals Management Performance
The success or failure of an entity such as Corbus Pharmaceuticals often depends on how effective the management is. Corbus Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Corbus management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Corbus management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.26) | (0.27) | |
Return On Capital Employed | (0.34) | (0.36) | |
Return On Assets | (0.26) | (0.27) | |
Return On Equity | (0.28) | (0.30) |
Corbus Pharmaceuticals Workforce Analysis
Traditionally, organizations such as Corbus Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Corbus Pharmaceuticals within its industry.Corbus Pharmaceuticals Manpower Efficiency
Return on Corbus Pharmaceuticals Manpower
Revenue Per Employee | 0.0 | |
Revenue Per Executive | 0.0 | |
Net Loss Per Employee | 1.4M | |
Net Loss Per Executive | 4M | |
Working Capital Per Employee | 5M | |
Working Capital Per Executive | 14.1M |
Additional Tools for Corbus Stock Analysis
When running Corbus Pharmaceuticals' price analysis, check to measure Corbus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corbus Pharmaceuticals is operating at the current time. Most of Corbus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Corbus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corbus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Corbus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.